Shing Mirn Lee

Statistics

Publications

Citations

H-Index

Active since

2017

Affiliations

Columbia University Irving Medical Center(Current)

Columbia University

Shing Mirn Lee is an author at Columbia University Irving Medical Center specializing in oncology, medicine, and immune checkpoint blockade combinations.

Publications per year

2017–2022

Publications

A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder.

G. Joel DeCastro, Wilson Sui, Jamie S. Pak et al. · Journal of Clinical Oncology · 2017 · 11 citations

Medicine, Oncology, Urology +10

Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma.

Rachael A. Safyan, Gulam A. Manji, Shing Mirn Lee et al. · Journal of Clinical Oncology · 2022 · 11 citations

Medicine, Oncology, Pharmacology +17

1–2 of 2